NEW YORK--(BUSINESS WIRE)--Mar. 16, 2021-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on March 15, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee. The inducement grants were approved by the Company’s compensation and talent strategy committee pursuant to a delegation by the Company’s board of directors and were made as a material inducement to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his employment compensation.

The inducement grants consisted of a non-statutory option to purchase 125,000 shares of the Company’s common stock, a grant of 60,000 restricted stock units for shares of the Company’s common stock and a grant of 10,000 restricted stock units for shares of the Company’s common stock.

The stock option has an exercise price of $6.425 per share, equal to the closing price of Iveric Bio’s common stock on March 15, 2021. The stock option has a ten-year term and vests over four years, with 25% of the shares underlying the option vesting on March 15, 2022 and an additional 2.0833% of the shares underlying the option vesting at the end of each successive month thereafter. The grant of 60,000 restricted stock units for shares of the Company’s common stock vests with respect to 25% of the shares underlying the grant on each of March 15, 2022, March 15, 2023, March 15, 2024 and March 15, 2025. The grant of 10,000 restricted stock units for shares of the Company’s common stock vests with respect to 100% of the shares underlying the grant on March 15, 2022. The vesting of each grant is subject to the employee’s continued service with the Company through the applicable vesting date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.

Iveric Bio 

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com.

ISEE-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005196/en/

Investor / Media Contact:
Iveric Bio
Kathy Galante, 212-845-8231
Vice President, Investor Relations and Corporate Communications
kathy.galante@ivericbio.com

Media Contact:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Source: IVERIC bio, Inc.